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Title: The senseless orphanage of Chagas disease. 
 
Abstract. 
Introduction: Chagas disease is caused by the parasite Trypanosoma cruzi. Endemic in 
21 American countries, there are ~7 million people infected, of which 14,000 die every 
year. Despite this burden, Chagas remains an orphan disease as it mainly affects poor 
communities with low economic and political power.  
Areas covered: there are two drugs available to treat the infection, but both have safety 
and efficacy issues. Investment in new treatments and other control measures has been 
historically neglected. This trend is changing and there are novel perspectives to put an 
end to this senseless orphanage. Research and development agenda of new therapies, 
diagnostic tools and biomarkers have moved forwards during the last decade; and patients 
associations have been active in promoting awareness of the disease all along. Besides, 
the WHO recently declared April 14th as the “World Chagas disease day”, which will 
increase the visibility of the disease and attract attention internationally.  
Expert opinion: efforts must focus in the prevention of new infections, but also in the 
management of the millions already chronically infected. This will require of an integral 
approach where increasing the number of trained health workers and generalizing access 
to diagnosis and treatment will be fundamental. 
 
Keywords: Chagas disease; Trypanosoma cruzi; orphan disease; treatment; clinical 
trials; patients´ associations; World Chagas disease day. 
 
Article highlights. 
 Chagas is an infectious disease caused by the parasite Trypanosoma cruzi that is 
endemic in 21 American countries, where reside most of the ~7 million people 
infected. 
 It is mainly transmitted by vectors that proliferate in infra-housing settlements 
linking the disease to a poor socioeconomic status; and since the affected people 
are from low-income communities with no political voice Chagas disease 
treatment and control has been historically neglected.  
 There are two drugs to treat the infection: benznidazole and nifurtimox. These 
are very efficient against the acute stage, but since this is mostly asymptomatic it 
is not diagnosed. Treatment is provided at the chronic stage, and by then its 
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efficacy is variable. In addition, both drugs entail long administration regimens 
that have frequent adverse effects associated. 
 Recent advances in more sensitive and specific diagnostics and point-of-care 
suited technologies, linked to a diversification of the drugs´ producers will 
contribute to generalize access to diagnosis and treatment in the near future. 
Moreover, Chagas disease is in the clinical trials arena, where alternative 
regimens of existing drugs as well as new drugs are being evaluated in the search 
of more efficacious and less toxic treatments. 
 Patients´ associations have greatly contributed to increase disease awareness and 
empower those affected by it. Sensitization must continue at all levels to ensure 
funding for research and development, and to invest in the training of health 
professionals in order to integrate Chagas disease patients care in the health 
systems from endemic and non-endemic regions. 
 
1. Introduction.  
1.1. Chagas disease origin and epidemiology. 
Chagas disease or American trypanosomiasis is a systemic parasitic disease 
caused by the flagellated protozoan Trypanosoma cruzi (T. cruzi). The infection is 
transmitted in the faeces of infected hematophagous vectors such as Triatoma infestans, 
that, upon a bloodmeal, defecate near the bite site or near mucosal tissue [1]. Parasites in 
the faeces will then gain access to the bloodstream through micro-injuries caused by 
scratching the bite site or through the mucosa [2]. Oral transmission due to the ingestion 
of parasite contaminated food or drink has been documented as well [3,4]. Vector-
independent transmission routes such as blood transfusion, organ transplant, and 
congenital have been described too [1]. Another possible route of infection can occur in 
case of a biohazard incident in the laboratory upon manipulating parasite containing 
samples [5]. 
There are over 100 species of transmission-competent insect vectors (family 
Reduvidae; subfamily Triatominae), which sustain a wild cycle that involves as many 
mammalian species as hosts and reservoirs [6]. These represent a continuous risk to 
people in rural endemic areas and make the eradication of the infection an almost 
impossible task. Vectors find a suitable habitat in adobe-walled houses and thatched 
roofs, still frequent in many regions of Latin America.  
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There is paleontological evidence of human T. cruzi infection as early as 9,000 
years ago in mummies from coastal and low valley sites in northern Chile and southern 
Peru, and 4,000 years ago in the mesothermal valleys around Cochabamba area, in what 
is now Bolivia [7–9]. Populations that lived in these areas abandoned their nomadic way 
of life for a stable one that included wild guinea pig breeding. This settlement favoured 
vector domiciliation and human infection since triatomine vectors obtained their food 
very easily from human beings. From these valleys, during the Inca Empire, the vectors 
and the human disease they transmitted were spread all over the American continent 
linked to migrations and Inca couriers, called “Chasquis”, who travelled the Inca roads. 
Spanish chronicles from the 16th and 17th centuries describe the presence of triatomine 
insects in homes in areas that today would be in Argentina, Bolivia, Chile and Paraguay 
[10]. Later on, Charles Darwin described the triatomine insects and detailed them biting 
himself on his “Voyage of the Beagle” in 1835, when he was crossing the Andes from 
Valparaiso (Chile) to Luxan (Argentina) [11]. But it was not until 1909 when Dr. Carlos 
Chagas, deployed in a northern area of the state of Minas Gerais in Brazil, first described 
the parasite, the insect vector and the human disease caused by the infection [12]. The 
joint full description of the elements driving to a disease, its symptomatology and 
epidemiological characteristics never before coincided in a single discoverer in the 
history of medicine. Thus, he was twice nominated to the Nobel Prize; and he was not 
elected for it neither of them [13].  
According to Coura et al the greatest expansion of human Chagas disease occurred 
during the 19th and 20th centuries [14]. This was mainly due to railways development in 
Brazil and Argentina, and to the related settlement of people in the inland regions of the 
countries. This expansion lasted until the 1980s, when Chagas disease was reported to be 
endemic in 21 countries of the American continent, there were 100 million people at risk 
of acquiring the disease, and more than 17 million were infected [15]. 
More recently, a second period of disease expansion has occurred as a result of 
the migration from endemic to non-endemic regions within Latin American countries and 
to countries in other geographical areas like northern North America and Europe (Figure 
1). For instance, it is estimated that Europe received around 2 million people from Latin 
America in the last decades [16]. Current figures of infected people living outside the so-
called endemic countries is very difficult to estimate due to the lack of reliable 
epidemiological studies in the countries of origin of the migrants and the diversity of legal 
status and access to health care of these people in the host countries. In 2007 Schmunis 
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estimated that there were between 38,000 and 676,000 T. cruzi-infected people in the 
USA [17]. In Spain, this estimate varies between 47,700 and 67,400 T. cruzi-infected 
people [18]. This latter range is explained by the different seroprevalence rates stated by 
the Pan American Health Organization (PAHO) in comparison to the values found upon 
diagnosing pregnant women from Chagas disease endemic countries in maternity wards 
from Valencia and Barcelona [18,19]. 
Despite its very important regional and international health impact, Chagas 
disease belongs to the group of Neglected Tropical Diseases (NTD) listed by the World 
Health Organization (WHO) [20]. These diseases share certain characteristics: they affect 
those with fewer resources; they are mostly chronic infections that can cause severe pain 
and/or lifelong disabilities; they are associated with the exclusion and stigmatization of 
the people who suffer from them; there are no vaccines and the available drugs to treat 
them have toxicity and efficacy issues [21]. 
The fight against Chagas began to be carried out jointly at the sub-regional level 
in the 1990s with the implementation of initiatives that brought together several countries 
that were endemic to the disease (Southern Cone, 1992; Central America, 1997; Andean 
Countries, 1998; Amazon countries and Mexico, 2004) [22]. These initiatives managed 
to significantly reduce the presence of vectors in households and the transmission of the 
infection through blood products. Altogether with a general improvement in the living 
conditions, including architectural improvements in homes that hinder the establishment 
of the vectors, reduced the estimated number of T. cruzi-infected people from 17 million 
in the 1980s to ~7 million today [1]. While the number of people affected has decreased 
significantly in recent decades, there are still 25 million people at risk of contracting the 
disease. Every year there are 30,000 new cases, 9,000 children are born with the disease 
and 14,000 people die as a result of Chagas disease [23]. Globally, Chagas disease 
imposes an annual burden of $627.5 million in health care costs and 806,170 DALY 
(Disability-Adjusted Life Year) [24,25]. 
 
1.2. Clinical features and diagnosis of the infection. 
Once a person becomes infected, the motile metacyclic trypomastigotes, which 
represent the first wave of mammalian infective parasite life forms, enter nucleated cells 
in blood and tissues and multiply intracellularly upon transforming into replicative 
amastigotes. These multiply inside the infected cells crowding their cytoplasm and 
transforming into trypomastigotes, another motile parasite stage that then bursts the 
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infected host cell and swims away to take the infection elsewhere [26]. The amount of 
parasites in blood and tissues grows exponentially during the first days of infection and 
lasts until the immune system develops a specific response to control their dissemination. 
This acute phase of the disease is 6 – 8 weeks long and is characterized by nonspecific 
symptomatology that frequently goes unnoticed: fever, headache, asthenia, anorexia, 
malaise, diarrhoea [1]. Nonetheless, a mortality rate of up to 5% has been reported, 
especially in children, whereas in oral transmission cases mortality can even be much 
higher [4,27]. From a microbiological point of view, at the acute phase the parasitaemia 
is high enough to be detected by direct or indirect classical parasitological techniques 
[28], or even more sensitively with molecular amplification techniques [29]. Levels of 
circulating parasites decrease as far as the specific immune response develops, which 
marks the beginning of the chronic phase. 
In the chronic phase of the disease parasitaemia is low and intermittent, but levels 
of anti-T. cruzi type G immunoglobulins (IgG) can be detected in serum, which allows 
serological diagnosis of the infection. This is asymptomatic in ~70% of the infected 
people, thereby leading to an indeterminate Chagas disease status [1]. Nonetheless, the 
remaining ~30% will develop a symptomatic form of the infection with cardiac and/or 
digestive involvement. Disruptions to heart and/or digestive tract tissues (oesophagus, 
colon) can be life-threatening if untreated, and it is estimated that in patients with 
symptomatic Chagas disease the possibility of premature death can reach up to 20% of 
the cases [30]. In immunocompromised patients, the disease can evolve from an 
asymptomatic indeterminate chronic phase to a reactivation situation, defined by high 
parasitaemia, with or without immediate clinical symptoms, which can be detected by 
parasitological methods [31]. 
Diagnostic methods for Chagas disease depend on the stage of the disease. In the 
acute phase and in reactivations, diagnosis is based on direct detection of parasites in 
blood either by classical parasitological techniques or by molecular amplification of T. 
cruzi DNA [15,32]. In immunocompromised hosts, the parasite presence can be detected 
in other fluids such as cerebrospinal fluid (CSF) [31]. Classic parasitological techniques 
such as the microhematocrit and Strout are based on direct visualization of the parasite 
under the microscope. These techniques have the advantage of being cheap and simple, 
but they are operator-dependent and their sensitivity largely decreases in case of 
parasitaemia levels lower than 40 parasites per ml [33]. In contrast, molecular methods 
such as the qualitative polymerase chain reaction (PCR) or the quantitative real-time 
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qPCR are more sensitive and less operator-dependent [34]. Unfortunately, they are not 
available in most diagnostic centres in endemic regions due to their higher cost and the 
need for advanced expensive equipment. When available, molecular diagnosis is the 
recommended method for the diagnosis of congenital Chagas disease, reactivations and 
acute phase [35,36]. In addition, qPCR is widely used at present to evaluate 
parasitological clearance after treatment in the context of research and clinical trials 
investigation [29]. The availability of an easy-to-use point-of-care (POC) molecular-
based diagnostic could change the current algorithm of congenital Chagas disease 
diagnosis, targeting for treatment infected newborns in a much faster fashion than with 
currently applied algorithms [37]. In this regards, an innovative Loop-isothermal 
amplification (LAMP) assay aimed to be used as POC test has been recently developed 
for the detection of T. cruzi-DNA [38]. It contains all the required reagents dried-up in 
the tubes lids and the fact that it relies on an isothermally working polymerase makes it 
possible to run it without requiring expensive thermal-cyclers [39]. 
The methods used to diagnose the infection in the chronic phase are serological, 
mainly based on the detection of specific anti-T. cruzi IgGs in serum samples [40]. 
Despite the advancements in sensitivity and specificity achieved with serological tests 
based on recombinant parasite antigens, the agreement of two serological techniques that 
are based on different antigen sets is still recommended to provide a conclusive result 
[41]. The most used serological method to diagnose chronic Chagas disease is the 
enzyme-linked immunosorbent assay (ELISA), of which there are many kits 
commercially available that provide very high sensitivity and specificity [42]. Other 
conventional serological techniques such as indirect immunofluorescence (IIF) or indirect 
hemagglutination assay (IHA) are less frequently used than the ELISAs, since they 
respectively require specific and expensive equipment (i.e. fluorescent microscope for 
IIF) or have a poorer performance than the former [43]. In terms of POC serological 
diagnostics, easy-to-use rapid diagnostic tests (RDTs), which are based on immuno-
chromatography, are gaining relevance in the last few years. They are simple to use, do 
not need cold-chain, and can be directly used in the field with a tiny drop of whole blood 
as sample. Plus, they are capable of yielding a results turnaround to the patient much 
faster than the ELISAs, while still maintaining a very good performance [44]. In fact, the 
combined use of two RDTs has been suggested as an alternative to the traditional chronic 




1.3. Chagas disease treatment. 
Benznidazole (BNZ) and nifurtimox (NFX) are the only two drugs approved for 
Chagas disease treatment [1]. They were both developed in the late 1960’s and there are 
no new treatments available since then [47,48]. The effectiveness of these treatments is 
affected by age, drug dose, stage of the disease, and area of origin of the patient, among 
other factors [49]. Parasitological and clinical efficacy of treatment in the acute phase in 
young patients can be up to 100% of the cases, especially in children under one year of 
age [50,51]. In contrast, when treatment is provided in the chronic phase, its efficacy has 
been estimated to range between 60% to 80% of the cases upon 12 months follow-up 
controls with qPCR [52,53]. Nonetheless, clinical efficacy is difficult to assess due to the 
natural course of the infection and the absence of early markers of treatment response or 
cure [54,55]. Accordingly to WHO guidelines, only negativization of serological titres 
can be interpreted as a readout of parasitological cure [15]. Notwithstanding, this 
serological reversion from positive to negative may take several decades to occur when 
treatment is administered in the chronic stage of the infection. As a consequence, 
currently available methodology to assess treatment response in the chronic stage is 
highly impractical [56].   
At present, administration of treatment is indicated for acute cases, congenital 
infections, reactivations, and those chronic stage infections without symptomatology 
(indeterminate disease) or with mild cardiac and/or digestive involvement [47,57,58]. The 
recommended dosage for BNZ regimens is 5 mg/kg/day divided into two doses for 30 to 
60 days; whereas for NFX, it is recommended to give 15 mg/kg/day divided into two or 
three doses for 60 to 90 days [48,59,60]. 
A very important issue regarding current therapeutic options for Chagas disease 
is the safety profile of the two drugs available. It has been described by different authors 
that between 48% and 86% of the patients treated with BNZ have some kind of adverse 
effect, resulting in treatment interruptions in 9% to 31% of the cases [61,62]. Similar 
figures have been reported in the case of NFX [63]. The most frequently observed adverse 
effects are dermatological, neurological and gastrointestinal, and they are generally mild 
[61-63]. Much less frequently, there is also a risk of serious life-threatening adverse 
effects such as severe neutropenia or Dress syndrome [64]. Thus, the paramount 
importance of setting up and maintaining pharmacovigilance programs to monitor the 
advent of these side-effects and the readiness to deal with them and minimize their impact 
in the patients´ wellbeing. 
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Besides the difficulties described, namely long treatments with frequent toxicity 
burden and the lack of reliable tests to early assess their effectiveness, access to the drugs 
still hinders the provision of treatment to people with Chagas disease. In 2012, data from 
WHO estimated that the number of people treated yearly was about 8,500 [65]. This 
means that since these treatments were launched, they have barely reached ~1% of those 
affected [66,67]. Looking at it from another point of view, it means that amongst the ~7 
million people currently infected by T. cruzi, more than 2.1 million will have cardiac or 
digestive complications, and that around 1 million people could die from this infection. 
Based on the present treatment success rate of 60% to 80%, if there were universal 
treatment coverage, 1.2 to 1.6 million of them could avoid the symptomatic form of the 
disease, live a better life and die from something else. 
 
2. Chagas disease as an orphan disease. 
2.1. Why is Chagas disease orphaned?  
The term “orphan disease” defines two different but related concepts. It is 
generally used to define a disease that affects a small number of individuals. Given the 
current number of people infected with T. cruzi, this definition cannot be applied to 
Chagas disease. However, “orphan disease” is also used as well to name diseases 
neglected by doctors [68]. This description fits perfectly with the current and past 
situation of Chagas disease. It can be said that Chagas disease was born orphaned of the 
attention of the scientific community and political interest. Without going any further, the 
description of the parasite, vector and human disease at the same time by Dr. Carlos 
Chagas was a milestone in the history of medicine, which never received the attention or 
recognition it deserved [13]. This probably had, and still has to do with the socioeconomic 
characteristics of the affected population. Carlos Chagas himself wrote: "There is an 
ominous fate in the study of Trypanosomiasis. Each work, each study, points a finger 
towards a poorly nourished population living in poor conditions; it points to an economic 
and social problem, which causes them (to the rulers) a tremendous discomfort because 
it is testimony of (their) inability to solve a tremendous problem [...]. It is a problem of 
“vinchucas”, which invade and live in poorly constructed, dirty rooms, with ignored, 
poor, undernourished inhabitants, with no hope or social horizon and that resist to 
cooperate. Talk about this disease and you will have governments against you" [69]. In 
2005, the Uruguayan writer Eduardo Galeano denounced in the book "Chagas, a silent 
tragedy" the fact that this disease, which takes several years to develop symptoms, affects 
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mostly poor people, and it is not interesting for the pharmaceutical industry, public 
opinion, and not even for governments, "...kills in silence [...], it kills the silence: those 
who live doomed to silence..." [70]. 
The orphanage of Chagas disease has to do with the fact that it mostly affects poor 
populations with little power of political pressure, which contributes to a state of 
invisibility as a health problem in the Americas that leads to a lack of investment in 
training of healthcare workers, health education of communities, and meagre research and 
development programs. In addition, it must be highlighted that the impact of the disease 
itself on the lives of the people affected by it largely contributes to a vicious poverty-
disease-poverty cycle, which transforms people at productive age into dependent 
individuals extending the disease impact onto household economics. On top of that there 
are structural, psychosocial, clinical and systemic barriers, which make access to 
treatment a challenging issue for those affected by the disease. Compared to other 
neglected diseases that particularly target the world’s poorest communities, the silence 
—both political and in the media— surrounding Chagas disease is striking and has 
delayed the implementation of already available solutions. 
Traditionally associated to poor rural areas, Chagas disease used to be a synonym 
of two very different and, in some ways, contradictory concepts: it meant “death”, and on 
the other hand “invisibility”, because it is an infection that can be imperceptible for the 
people who live with it all their lives. These features must drive to strengthen the efforts 
to promote awareness and training for health staff, and in particular, those who care 
directly for patients or affected populations [71]. Historically, health professionals in 
endemic areas were insufficiently aware of the disease impact as they did not acquire the 
knowledge about how to manage it. This has had a direct impact on the clinical aspects 
of patient care. The lack of attention towards Chagas disease in Latin American healthcare 
systems is partly explained by the fact that the books used for the training of health 
professionals are published in Europe or North America. In these regions, until the 
migratory phenomena of the year 2000s, Chagas disease was a virtually unknown disease 
and therefore it was absent or scarcely mentioned in these texts.  
On the other side, in academic discussions autoimmunity was long hypothesized 
to be the major mechanism for chronic Chagas disease pathology [72]. For many years, 
this hypothesis negatively contributed on the efforts to implement available anti-parasitic 
treatments and to develop more effective drugs. Fortunately, scientific evidences on the 
role of the T. cruzi parasite as a trigger for tissue damage accumulated over the last three 
10 
 
decades, providing a basis to reconsider this paradigm and to re-introduce anti-parasitic 
treatment for chronic adult patients. [49,73–75]. 
In connection with the lack of awareness of health care workers, the neglect of 
Chagas disease also involves health decision makers. It was not until 1986 that the first 
regional program for the control of Chagas disease was established in Tupiza, Bolivia 
[76]. Since then, national Chagas programs have been implemented in the region, with 
the creation of diagnostic and treatment guidelines, which are not always coincident [77–
80]. Finally, in 2018, the first consensus guideline at regional level was endorsed by 
PAHO/WHO [41]. Before that, discrepancies in the indications for treatment in different 
national guidelines meant that, for example, treatment was not universally recommended 
in patients over 19 years of age with an indeterminate chronic form of the disease, which 
clearly represents a missed treatment opportunity. The reason for not recommending 
treatment in adult patients was mainly due to the lack of an early cure marker, since the 
only cure marker currently accepted is serological negativization and this can take 
decades to occur [36]. 
Perhaps the sole exception to the absence of specific attention to Chagas disease 
was the regional implementation of vector control programs. This, together with the 
improvement in housing habitability conditions (although these were not specifically 
aimed at controlling the disease), led to a 40% decrease in the number of people affected 
over time: from the ~17 million in the 1980s to the ~10 by the end of last century and ~7 
million today [23]. However, vector control programs have been irregularly implemented 
in the region, and become an incomplete and inefficient strategy unless they are not 
accompanied by other specific measures for disease control such as providing information 
and education to the community, training healthcare personnel, and enabling widespread 
access to diagnosis and treatment. 
 
2.2. Need of tools to improve disease control and management. 
Tools to detect anti-T.cruzi immunoglobulins at the chronic stage and 
parasitological and/or molecular diagnostics for the diagnosis of acute infection are 
nowadays available [81,82]. Despite they provide valuable information on the infection 
status, they cannot inform on the clinical prognosis of the disease neither on the treatment 
efficacy (or spontaneous cure) in a short period of time [54]. As already mentioned, a 
positive serological result takes many years to become negative upon administration of 
treatment and no re-exposure to the infection. Thus, it is not possible to rely on current 
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serological tests in order to address response-to-treatment timely. On the other hand, 
although molecular-based techniques are highly sensitive to assess acute T. cruzi 
infection status, treatment administration usually occurs during the chronic stage when 
parasitemia is low and intermittent. By then a positive qPCR result at follow-up will 
indeed indicate a treatment failure event, but a negative outcome cannot rule out the 
presence of undetected tissue hidden parasites that could relapse later on. Thereby, the 
lack of appropriate biomarkers to early assess response to treatment greatly limits overall 
the opportunity to give an accurate response to patients about the efficacy of their specific 
treatment. In addition, this shortage also hinders the evaluation of the efficacy of new 
therapeutic strategies tested through clinical trials. These are major barriers towards 
generalizing access to diagnosis and treatment, and strong reasons to consider Chagas 
disease an orphan disease. 
The aim of several ongoing studies is to identify and validate markers to early 
address disease prognosis and/or therapeutic response. These studies have evaluated both 
parasite-derived markers [83–85], as well as host-derived ones [86–89]. The latter could 
be classified into three main groups: (i) immunological markers (cytokines) elicited by 
the host cellular response to the infection; (ii) biochemical biomarkers, such as 
hypercoagulability markers, fragments of apolipoprotein A1 (ApoA1), or transforming 
growth factor beta (TGFβ); and (iii) inflammatory markers of cardiac damage (e.g. type-
B natriuretic peptide (BNP) or highly-sensitive protein C), which have been perhaps the 
most studied of all and unfortunately were not very good to follow disease progression 
[90]. Very recently, the use of cytokine IL17A as biomarker of treatment response has 
generated expectation [91], but further studies should be implemented to better 
characterize and validate them, especially in chronically infected adult population. On the 
other hand, expectations have been as well deposited on a promising group of parasite-
derived biomarkers, which mostly encompass parasite surface molecules [83–85,92]. The 
future availability of different types of long-awaited early response-to-treatment 
biomarkers, and the corresponding tests based on them will be crucial to “un-orphan” 
Chagas disease.  
 
2.3. Advancements towards improved therapeutic interventions. 
No new treatments for Chagas disease have been approved since the 1970s. As 
indicated above, BNZ and NFX are the only medications available for the treatment of T. 
cruzi infection. However, despite belonging to the list of essential medicines of the WHO, 
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they are available to less than 1% of the infected individuals [66,67]. Other challenges to 
face include their safety profile and variable efficacy accordingly to the stage of the 
disease they are administrated. BNZ production has had many ups and downs during the 
last decades. Roche was its only manufacturer until 2003, when it stopped production and 
commercialization. Then, it transferred the manufacturing technology and rights to the 
Brazilian government, which assigned the production of BNZ to the Public 
Pharmaceutical Laboratory of the State of Pernambuco (LAFEPE) (Figure 2A). Then 
BNZ production stopped from 2003 to 2008. LAFEPE was at that time the only producer 
of BNZ in the world. However, LAFEPE did not have the Good Manufacturing Practices 
(GMPs) certification for the production of the drug, which prevented the possibility of 
commercialization to other countries and there was a dramatic shortage. In 2011, the 
Argentine pharmaceutical laboratory ELEA began the production of BNZ (Figure 2A), 
becoming the only producer of BZN able to commercialize it through the PAHO fund. 
Nowadays, LAFEPE and ELEA (with its North American subsidiary EXELTIS), can 
produce and distribute BNZ, but being the only two companies in the market, competition 
will hardly influence price regulation so as to have BNZ at an affordable price. Similarly 
occurs with NFX, which is produced by Bayer and GADOR, and in most endemic 
countries is only accessible for treatment through donations to national Chagas programs 
(Figure 2B).  
According to the price list published by PAHO in its strategic fund reference 
prices [93], the estimated cost of BNZ treatment for an adult is ∼100 USD [94,95]. In any 
case, it is yet incredible that when there is access to the drugs, this is often through 
complicated drug application processes that sometimes involve weeks or months until 
having them delivered. Such application processes are not usually accessible to primary 
care physicians who are most aware of the needs and responsible for their prescription. 
The immediate consequence is that a doctor in an endemic country sadly may not have 
the chance to offer treatment in case of need. 
The troubles with the drugs´ production and distribution listed beforehand relate 
to the neglect of the disease by the political statement, as much as with the lack of 
commercial interest of pharmaceutical companies. The latter has a large impact on the 
research and development of new drugs for Chagas disease too. Although it affects a large 
number of people, their very low purchasing capacity makes the potential market 
unattractive to pharmaceutical companies´ drug discovery efforts. Thereby, with no 
revenue foreseen it is complicated that private initiatives take the risk to invest in anti-T. 
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cruzi drug development. However, some non-profit initiatives in recent years are leading 
a change in this regard [96]. After decades without any movement at all, in the past few 
years up to three clinical trials evaluating new drugs for Chagas disease have been carried 
out [52,97,98]. In all cases, posaconazole and ravuconazole (its prodrug E1224) failed to 
yield the level of parasitological clearance achieved by the gold-standard BNZ  
[52,97,98]. Even so, the fact that these clinical trials took place is hopeful by itself. To 
illustrate the difficulty of conducting clinical trials in some endemic areas, it should be 
enough to point out that the first clinical trial conducted in the history of Bolivia was the 
mentioned E1224 [52]. Although the outcome of such experience did not contribute to 
change the treatment of Chagas disease, it left a mark in the country in terms of acquired 
experience and training of the personnel involved. These are key features towards the 
performance of both current and future studies, such as FEXI, BENDITA and TESEO 
among others [99]. Similarly, although the results from the BENEFIT trial were 
controversial, it marked a milestone in Chagas disease clinical research being the first 
Phase III study ever performed [99]. In this regards it represented a major advancement 
in the field as it established a large multinational clinical network for its performance that 
involved institutions from several Latin American countries. 
Amongst the new drugs under evaluation for Chagas disease treatment, perhaps 
the most promising is fexinidazole (FEXI). Notably, its use for the treatment of African 
trypanosomiasis, a parasitological disease caused by T. cruzi closely related protozoan 
species T. brucei gambiense and T. b. rhodensiense, has been very recently approved 
[100,101]. At present, there are pending results of a Phase II study evaluating FEXI 
administration to chronic Chagas disease patients [102]. An observed increased scientific 
interest, altogether with the improvement of the drug discovery techniques, hold promise 
towards finding a better drug for Chagas [103]. Nonetheless, currently ongoing efforts 
will need to be sustained and paired with an adequate investment, otherwise there is a 
high risk of a slow and inefficient progression [104]. 
 
2.4. Patients´ involvement. 
Regarding the patient’s active role, there have been some significant advances in 
the last decade. In 2010, more than 20 associations from all over the world gathered to 
create the International Federation of Associations of People Affected by Chagas Disease 
(FINDECHAGAS). Members of the associations that are part of FINDECHAGAS chose 
to be identified as “affected” people and not as “infected”. In deciding to be represented 
14 
 
through non-stigmatizing word choice, the members of FINDECHAGAS are promoting 
a transformation in the way we traditionally look at those who suffer these kinds of 
diseases. 
The need of increasing awareness about Chagas disease is a common gap for both 
patients and health staff. To fill this gap, both communities must work together. On 28th 
April 2015, the Food and Drug Administration (FDA, United States of America) held a 
public meeting to hear people with Chagas disease about their condition, its impact on 
their daily life, and their perspectives on approaches to treating the disease. In this 
meeting, besides patients and patient advocacy organizations, there were various 
stakeholders in the drug development process, health care providers, academic experts 
and industry experts. From the patient’s point of view, the most important input provided 
was the significant lack of awareness and understanding of Chagas disease by the 
healthcare community. Patients participants identified struggling with fear of future 
symptoms, social isolation, difficulty in finding others to discuss their experiences with, 
and the frustration of living with a condition that was not well understood [105]. 
In the last assembly of FINDECHAGAS, held in Veracruz (Mexico) in 2018, 
patients associations brought back again the need to be more visible, the need to be 
listened to [71]. They requested the support of all health stakeholders and especially from 
the Chagas disease Global Coalition in order to submit the petition of a Chagas disease 
World Day to the World Health Assembly. This submission was approved, and the 
official day was voted in the WHO’s 72nd World Health Assembly in May 2019. Next 
April 14th 2020 will be the first official global day for Chagas disease (Figure 3) [106]. 
That very same day in 1909, doctor Carlos Chagas made the first diagnosis of the disease 
to the child Berenize Soares in Minas Gerais, Brazil [107]. 
 
3. Perspectives to get Chagas disease un-orphaned. 
One of the most powerful arguments to get the attention of governments is to focus 
on the huge economic consequences of maintaining this disease and its tremendous public 
health impact ignored, neglected. The estimated economic burden of Chagas disease was 
calculated between 6,500 and 7,190 million dollars per year [24]. These figures would 
justify by themselves that governments and policy makers believed that investing on 
Chagas disease control measures can be a way to improve the health of the population 
and, at the same time, improve the country's economy [108,109]. For example, a cost-
benefit study of a congenital Chagas detection program conducted in Bolivia concluded 
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that with an investment of 1.5% of the annual socioeconomic cost of all congenital 
Chagas cases it would possible to diagnose and treat all children born in Bolivia with this 
infection [110]. 
The fight against Chagas disease can benefit from the Sustainable Development 
Goals (SDGs), which involved setting out a new roadmap on NTDs for the next decade, 
with specific targets to advance towards the control of Chagas and ultimately its 
elimination as a public health challenge. Chagas disease is included implicitly in some 
targets of SDG Goal 3, which is related to health issues. Particularly, Chagas disease is 
directly addressed in target 3.3: “…on the end of epidemics of Neglected Tropical 
Diseases by 2030”; and indirectly in other targets such as: target 3.4 (“…reduce mortality 
from noncommunicable diseases…”), target 3.8 (“…achieve universal health 
coverage…”), and due to its congenital transmission route also by target 3.7 (“…ensure 
universal access to sexual and reproductive health care services…”), plus target 11.1 
(“…adequate, safe and affordable housing…”) [111]. 
In addition, institutional coordination will be fundamental at the transnational 
level in endemic areas as well as in non-endemic countries. For example, interventions 
regarding vector control, information and education of the communities or diagnosis and 
treatment in an area such as the Gran Chaco, which includes vast extensions of Bolivia, 
Paraguay and Argentina, will be much more efficient the better coordinated and the more 
similar they are in between those countries. Maintaining vector surveillance and control 
programs is yet at the frontline of the fight against Chagas, so they must be solidly 
maintained and expanded to areas where it is not applied now. Based on this premises, it 
should be possible to implement more advanced control strategies [112].  
Like many other infectious diseases, Chagas disease must be controlled through 
comprehensive programs that offer a broad range of interventions in addition to case 
management (diagnosis and treatment). These include Chagas disease information and 
education to the communities and widespread training of healthcare personnel. For the 
latter it will be essential to make efforts to include specific training on Chagas disease for 
health professionals in the curricula of schools and universities. This will allow creating 
a foundation on which to establish control and management programs as well as it will 
generate a prepared scientific community that is better connected with the reality of its 
environment. Although it is very important, counting with well-informed health 
professionals will not change the reality of the disease, all of a sudden bringing it to the 
focus of the common interest. For this, information, education and communication (IEC) 
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actions with civil society are yet very necessary to find tools that can help control the 
disease and manage its daily impact [113]. 
 If we assumed that of all of the above said (greater government interest, 
coordinated transnational policies, trained professionals and a very involved civil society) 
is eventually achieved, there would still be a lot of work to do in terms of improving 
access to diagnosis and medications. It must be highlighted that there are already many 
diagnostic tools and two drugs available for this purpose. Notably, we can count as well 
with positive experiences of training primary health doctors, in procedures where they 
concentrate efforts on the access to diagnosis and treatment, and are in connection to other 
specialists in case their intervention would be necessary [112]. Such a strategy could 
partly mitigate the current problems of access to diagnosis and treatment experienced by 
a population that is frequently dispersed geographically and with little accessibility to 
hospital care. 
The implementation of this kind of initiatives would yet leave us with an 
insufficiently studied disease from which there is much to be understood (e.g. its 
pathophysiology); that lacks of a vaccine; for which the only available chemotherapeutic 
options have a worrying safety profile where frequent adverse effects are observed; and 
that has no biomarkers available for the evaluation of therapeutic response nor any to 
diagnose disease progression. Thus, in-depth knowledge will be much needed towards 
the control and adequate management of Chagas disease impact. This will undoubtedly 
require of an unambiguous investment in research and development of biomarkers, 
locally adapted diagnostic algorithms, and new therapeutic interventions, including the 
search for an effective vaccine. 
As an orphan disease, Chagas disease treatment should be benefited by 
accelerated procedures to facilitate marketing authorization and drug availability. These 
procedures can be priority review, fast-track approval and accelerated approval. 
However, no such legislative benefits regarding orphan drugs exist in any of the endemic 
countries. From the USA as well as the countries of the European Union, where these 
mechanisms do exist, an impulse is needed to recognize Chagas as an orphan disease. 
This could boost the use of legal resources available that could help facilitate marketing 





For the last two decades, Chagas disease is slowly leaving anonymity and 
beginning to have a higher presence in the public health landscape. This is in part related 
to the healthcare attention change associated to population movements of the late 20th and 
early 21st centuries. Europe became a destination for around 2 million people originating 
from Chagas disease endemic countries, and management of the disease became a 
challenge for European health care systems and research groups. This challenge is now 
reflected in the performance of clinical trials centered on treating Trypanosoma cruzi 
infections. Nonetheless, only 3 out of the 47 Chagas disease interventional clinical trials 
registered have evaluated the use of drugs different from BNZ and NFX [99]. Moreover, 
despite this very welcomed wave of clinical studies, to date there is no new treatment that 
has yet passed Phase II of evaluation. As a result, it is very unlikely that a new anti-T. 
cruzi drug becomes available within the next 5 years. However, what these trials have 
very well established is that currently available drugs can indeed be used in a primary 
health care context with good results. 
In the diagnosis arena, there has been as well a remarkable progress.  
Conventional serological tests such as the ELISAs based on recombinant antigen sets now 
provide a very high sensitivity and specificity. There is as well a plethora of RDTs based 
on immuno-chromatographic techniques commercially available that could be used as 
POC diagnostics for the chronic infection. Some of them have shown a performance 
comparable to the ELISA tests, with the advantage over conventional methods of being 
very simple to use and well-suited to work in the field. However, while serological 
methods are the standard of use in the chronic stage, sensitive and reliable methods to 
diagnose the acute stage of the infection are still missing. Molecular diagnostics such as 
the real-time qPCR are very sensitive for the detection of the circulating parasites during 
the acute phase, but the reagents´ costs and the requirement of expensive equipment and 
highly-trained personnel are yet disadvantages to overcome towards their implementation 
in endemic regions with low resources. Innovative developments such as the LAMP assay 
could represent a solution to this problem providing the sensitivity of a molecular-based 
detection of the parasite in a POC test suitable for healthcare facilities with poorly 
equipped laboratories. 
Despite the aforementioned advances, a major problem towards an improved 
management and control of Chagas disease is still the lack of biological markers of 
disease prognosis and cure. Accordingly to the WHO recommendation, only the 
serological reversion from positive to negative status evaluated by conventional serology 
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is accepted as cure marker. But this is most impractical as it can take several years or even 
decades to occur upon treatment administration. Undoubtedly this is a field of research 
that needs more investment, as to date there is not a well-defined set of biomarker 
candidates, neither for the prognosis of the disease pathology or for the evaluation of 
treatment response. 
In contrast, a remarkable feature to highlight within the last few decades is the 
growing involvement of patients and affected population in spreading disease awareness. 
More than 20 patients’ associations form the International Federation of Associations of 
People Affected by Chagas Disease (FINDECHAGAS). The common main objective of 
these associations is to make Chagas disease more visible, to increase the awareness about 
it. In this context, the World Health Assembly recently approved to declare April 14th as 
the international day of Chagas disease. It is expected that this will help to attract further 
attention on this public health problem and commit countries with affected populations 
to accomplish and maintain Chagas disease control interventions. In relation to the 
former, there is yet an urgent need to specifically train healthcare workers in the disease 
management, both in endemic as well as in non-endemic regions. The consensus 
guideline issued by the PAHO - WHO for the diagnosis and treatment of Chagas disease 
patients could be used as a basis for healthcare professionals training.  
Overall, the funding and political measures required towards the availability of: 
(i) well-established and widespread vector control mechanisms; (ii) safer and more 
efficacious drugs, especially against the chronic stage; (iii) reliable and practical 
diagnosis algorithms that are better suited to the reality of highly endemic regions distant 
from reference laboratories; (iv) biomarkers to early assess cure and/or disease 
progression; and (v) adequately trained and prepared healthcare personnel and health 
systems, they must all be accompanied by the commitment of governments and 
international institutions that nurture trans-national cooperation. Ensure a generalized 
access to Chagas disease diagnosis and treatment is a pending subject that deserves the 
compromise of all involved actors (patients´ associations, academia, pharmaceutical 
companies, governments, international agencies,…) in order to grant all aforementioned 
features to the affected populations as soon as possible. 
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